Table 2.

Summary of clinical reports using antioxidants or NAC in G6PD^def.

Treatment	Dose	Duration	Outcome	Type of Study	Reference
α-tocopherol	adults: 800IU/day, oral children: 400 IU/day, oral	60 days	↑ Hb levels ↑ erythrocyte number ↑ packed cell volume ↓ reticulocytosis ↓ serum bilirubin	not registered	[126]
α-tocophero-acetate	800 IU/day, oral	12 weeks, 1 year	↑ Hb levels ↑ erythrocyte half-life ↓ reticulocytosis	not registered	[55]
α-tocophero-acetate	1000 IU/day, oral	24 weeks, 1 year	no improvements		[127]
α-tocopherol	800 IU/day, oral	8 weeks	↑ Hb levels ↑ erythrocyte half-life ↓ reticulocytosis	not registered	[56]
α-tocopherol-acetate	800 IU/day, oral	16 weeks	↑ erythrocyte survival ↓ reticulocytosis Failed to abolish hemolytic process	case study	[54]
α-tocopherol	400 IU/day, oral	4 weeks	no improvements	case study	[58]
α-tocophero-acetate	2000 IU/day, oral	4 weeks	no improvements	case study	[57]
α-lipoic Acid	600mg/day, oral	28 days	↑ GSH, TAC, and catalase activity ↓ lipid peroxidation in both groups	not registered	[62]
α-lipoic Acid	600mg/day, oral	28 days	↑ TAC at resting did not increase response to acute exercise stress	NCT02937363	[63]
N-acetylcysteine	initial dose-10g, IV 5g/4hr, IV	56 hrs	↑ hemolysis, unclear if due to NAC	case study	[128]
N-acetylcysteine	1200mg/x2, oral	1 year	↑ brief psychiatric rating score	case study	[129]
N-acetylcysteine	10g/x3/day, IV 600mg/x2/day, IV 600mg/x2/day, IV	1 day 7 days 5 days	↓ hemolysis indices after each treatment	case study	[25]